← Browse by Condition
Medical Condition
nasopharyngeal cancinoma npc
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 3
NCT07067268 Phase 2
Recruiting
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Enrollment
76 pts
Location
China
Sponsor
Fudan University
NCT06676722 Phase 2
Recruiting
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
Enrollment
20 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT07232680
Recruiting
Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy
Enrollment
500 pts
Location
Taiwan
Sponsor
Cheng-En Hsieh
NCT06669611 Phase 3
Recruiting
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Enrollment
242 pts
Location
China
Sponsor
Sun Yat-sen University
NCT07311772 Phase 3
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
Enrollment
244 pts
Location
China
Sponsor
Sun Yat-sen University
NCT06788002 Phase 2
Recruiting
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
Enrollment
26 pts
Location
China
Sponsor
Hunan Cancer Hospital
NCT06846450 Phase 3
Recruiting
Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC
Enrollment
470 pts
Location
China
Sponsor
Lin Kong, MD